Use of n-'5-'4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension

The method according to claim 10, wherein the pulmonary hypertension is selected from primary pulmonary hypertension or secondary pulmonary hypertension.

The method according to claim 10 wherein a daily dose of 100 to 1000 mg of COMPOUND I of the formula I is administered to an adult human.

The method according to claim 10 wherein the pulmonary hypertension is not caused or accompanied by pulmonary fibrosis.

The method according to claim 10 wherein N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine of the formula I is in the form of a pharmaceutically acceptable acid addition salt.

A combination which comprises (a) N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine (designated hereinafter as COMPOUND I) and (b) at least one compound selected from the group comprising calcium channel antagonists, anticoagulants, endothelin receptor blockers, angiotensin-converting enzyme inhibitors, diuretics, and phosphodiesterease inhibitors for the manufacture of a medicament for the treatment of pulmonary hypertension.

A method of treating humans suffering from pulmonary hypertension which comprises administering to a said human in need of such treatment a dose, effective against pulmonary hypertension, of N-15-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl)-4-(3-pyridyl)-2-pyrimidine-amine of the formula I

• or a pharmaceutically acceptable salt thereof.